RVMD

Revolution MedicinesD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

Peers tracked

U.S. public peers

Grade Position

Below peers

vs peer average

RVMD vs peer average

34/100

RVMD vs. peer average (D vs. C)

Grade spread

B 3 · C 4 · D 3

Graded peers loaded

Coverage

10 graded

100% of tracked

Peer overview

AMGN is the first available peer comparator.

Amgen is the closest candidate in the packet for a marketed KRAS benchmark because Lumakras gives investors a real-world frame for RAS-targeted oncology commercialization, although Amgen is far more diversified and mature than RVMD.

✓Peer source comes from the stored AI memo or peer model

✓Grades and factor rows use RankAlpha API data when available

✓Missing peer scores remain blank instead of being estimated

✓Side-by-side comparison keeps the data contract visible

Top peerAMGNAmgen

RVMD

Revolution Medicines

AMGN

Amgen

Grade

Momentum

Value

Sentiment

Setup Bias

Net —

Market Cap

Posture

Defensive

Open Side-by-Side Comparison Compare all

Grade position vs AMGN

RVMD / AMGN

Grade Position

Below peers

RVMD vs. peer average (D vs. C)

34/100

Momentum

RVMD

Value

AMGN

Sentiment

AMGN

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank

Ticker

Company

Grade

Grade score

vs RVMD

AMGN

40/100

Even

ONC

80/100

-2

GILD

60/100

-1

NTRA

Natera Inc Common

80/100

-2

Agilent Technologies Inc Common

40/100

Even

AMGN is the first peer returned for this comparison set.